RenalGuard system in high-risk patients for contrast-induced acute kidney injury

Carlo Briguori, Gabriella Visconti, Michael Donahue, Francesca De Micco, Amelia Focaccio, Bruno Golia, Giuseppe Signoriello, Carmine Ciardiello, Elvira Donnarumma, Gerolama Condorelli

Research output: Contribution to journalArticlepeer-review


Background High urine flow rate (UFR) has been suggested as a target for effective prevention of contrast-induced acute kidney injury (CI-AKI). The RenalGuard therapy (saline infusion plus furosemide controlled by the RenalGuard system) facilitates the achievement of this target. Methods Four hundred consecutive patients with an estimated glomerular filtration rate ≤30 mL/min per 1.73 m2 and/or a high predicted risk (according to the Mehran score ≥11 and/or the Gurm score >7%) treated by the RenalGuard therapy were analyzed. The primary end points were (1) the relationship between CI-AKI and UFR during preprocedural, intraprocedural, and postprocedural phases of the RenalGuard therapy and (2) the rate of acute pulmonary edema and impairment in electrolytes balance. Results Urine flow rate was significantly lower in the patients with CI-AKI in the preprocedural phase (208 ± 117 vs 283 ± 160 mL/h, P 0.32 mg/kg (HR 5.03, 95% CI 2.33-10.87, P

Original languageEnglish
Pages (from-to)67-76
Number of pages10
JournalAmerican Heart Journal
Publication statusPublished - Mar 1 2016

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'RenalGuard system in high-risk patients for contrast-induced acute kidney injury'. Together they form a unique fingerprint.

Cite this